Dr. Reddy’s (NYSE: RDY) schedules March 2026 analyst and investor group meets

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its upcoming schedule of analyst and institutional investor meetings. The company’s management plans to participate in two group meetings with investors in early March 2026.

On March 4, 2026, management will attend an in-person group meet organized by Ambit Capital in Hyderabad from 11:00 to 13:30 IST. On March 5, 2026, they will join a virtual group meet organized by Goldman Sachs from 11:15 to 12:15 IST. The company notes that this schedule may change due to any exigencies on the part of investors or the company.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

February, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                               Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ___________

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ___________

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                                     No  x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-___________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated February 27, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: February 27, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:   + 91 40 4900 2900 Fax:  + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

February 27, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings

This is to inform that the Company’s management will be participating in the following investor conference with single institution(s)/ investor groups:

Date	Organized by	Location	Meeting mode	Nature of meet	Timing
04.03.2026	Ambit Capital	Hyderabad	In-Person	Group Meet	11:00 - 13:30 IST
05.03.2026	Goldman Sachs	-	Virtual	Group Meet	11:15 - 12:15 IST

Please note that the schedule of the aforesaid meeting is subject to change due to any exigencies on the part of Investors / Company.

This is for your information. 

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

FAQ

What is Dr. Reddy’s Laboratories (RDY) disclosing in this Form 6-K?

Dr. Reddy’s Laboratories is disclosing its upcoming schedule of analyst and institutional investor meetings. Management will participate in two group meetings with investors in early March 2026, one in-person in Hyderabad and one virtual, subject to possible schedule changes.

When and where are Dr. Reddy’s (RDY) investor meetings scheduled in March 2026?

The company has two investor group meetings scheduled in early March 2026. On March 4 in Hyderabad, management meets investors in person, and on March 5 they participate in a virtual group meeting, with precise time slots provided for each session.

Who is organizing the upcoming Dr. Reddy’s (RDY) analyst and investor conferences?

Two firms are organizing the upcoming Dr. Reddy’s meetings. Ambit Capital will host an in-person group meet in Hyderabad on March 4, 2026, while Goldman Sachs will host a virtual group meet on March 5, 2026, both with defined time windows.

What is the format of Dr. Reddy’s (RDY) March 2026 analyst and investor meetings?

Both sessions are described as group meets with analysts or institutional investors. One meeting is in-person in Hyderabad and the other is virtual, indicating management will address multiple investors together rather than holding individual one-on-one discussions.

Can the schedule of Dr. Reddy’s (RDY) analyst and investor meetings change?

Yes, the company notes that the meeting schedule is subject to change. Adjustments may occur due to exigencies on the part of either the investors or the company, meaning timing or participation could be modified if unexpected circumstances arise.

Which stock exchanges list Dr. Reddy’s Laboratories referenced in this disclosure?

The disclosure references listings on multiple exchanges. It mentions the National Stock Exchange of India (DRREDDY), BSE Limited (500124), the New York Stock Exchange (RDY), and NSE IFSC Ltd. (DRREDDY), highlighting the company’s presence in both Indian and U.S. markets.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 38.5 KB